8 April 2021
The Barkby Group PLC
("Barkby", the "Group" or the "Company")
Verso Biosense signs agreement with London Women's Clinic
The Barbky Group PLC is pleased to announce that Verso Biosense, an innovator in UK femtech focused on improving women's health, is delighted to announce the signing of its second product collaboration agreement with one of the UK's leading fertility clinics, London Women's Clinic.
London Women's Clinic will collaborate with Verso, using its uterine monitoring device to refine the technology and biosensing platform to meet the needs of its fertility patients. Verso's platform captures critical in-vivo, biosensing data for optimisation and personalisation of IVF treatment, providing actionable insights for clinicians and patients.
The London Women's Clinic provides world-class fertility care to women and couples across England and Wales. Since it was established in 1985 in Harley Street, it has pioneered many of the routine techniques used to treat fertility today. London Women's Clinic has regional centres in the South East, North East, and West of England, and Wales.
Joseph Cefai, Head of Product Development at Verso Biosense, commented:
"We are delighted to announce our partnership with the London Women's Clinic, a true leader in providing world-class fertility treatment to women and couples. It is testament to the potential of our ground-breaking platform that this is the second partnership we have announced in the space of a few of weeks, following our agreement with Homerton University Hospital in March. We are moving at pace to provide our monitoring platform to meet the needs of patients and we are delighted by the progress that we are making."
Enquiries:
The Barkby Group PLC |
|
Charles Dickson, Executive Chairman Douglas Benzie, Chief Financial Officer |
|
|
|
finnCap Ltd (Nomad and Broker) |
+44 (0) 20 7220 0500 |
Carl Holmes/Simon Hicks (corporate finance) Tim Redfern/Richard Chambers (ECM) |
|
|
|
Camarco (Financial PR) |
+44 (0) 20 3757 4994 |
Jennifer Renwick/Jake Thomas
|
|
Notes to editors
The Barkby Group PLC is a diversified group of high growth, high quality businesses run by an entrepreneurial and experienced management team. The existing wholly owned businesses within Barkby include; Commercial Property Development, Barkby Hospitality (comprising Barkby Pubs and Workshop Coffee) and Centurian Automotive Ltd.
In addition to these businesses, Barkby Life Sciences has invested in Verso Biosense, a digital health company aiming to transform Women's Health with precision medicine, and its subsidiary Cambridge Sleep Sciences Ltd has launched, SleepHub™, a device which improves and facilitates natural sleep.
Barkby's strategy is to accelerate and maximise opportunities within its existing businesses as well as continue to source and invest in cash generative, growth businesses with the ability to disrupt.